ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Toshiharu Korekane Code No: 4528 at the 1st section of the Tokyo / Osaka Stock Exchange INQUIRIES: Kinya Morimoto, Executive Director, Public Relations (Phone: 06 6263 5670)

Announcement on Acquisition of the Company's Own Shares

(Pursuant to the Provision of its Articles of Incorporation in accordance with Article 165 (2) of the Corporate Law of Japan)

Ono Pharmaceutical Co., Ltd. announced that it resolved an acquisition of its own shares pursuant to article 156 of the Corporate Law of Japan which is applicable in accordance with Article 165 (3) of the Corporate Law at the meeting of its Board of Directors held today.

1. Reasons for the acquisition

The shares will be acquired for the purpose of improving capital efficiency and as a part of measures for returns to shareholders.

2. Details of the acquisition

(1)	Class of shares to be acquire	ed	Common stock of the company
(2)	Total number of shares to be	e acquired	Up to 5.5 million shares (equivalent to 4.55% of a total number of the company's shares issued)
(3)	Aggregate amount of acquisition cost		Up to JPY 30 billion
(4)	Period of Acquisition	From April 15	, 2008 (Tue) to September 30, 2008 (Tue)

(Reference)

Status of the company's treasury stock as of March 31, 2008)

Total number of the company's shares issued (excluding treasury stock) 113,383,848 shares

Total number of treasury stock

7,463,652 shares